Home > Marketing > Global Infertility Testing Market Outlook 2024: Market Trends, Segmentation, Market Growth and Compe

Global Infertility Testing Market Outlook 2024: Market Trends, Segmentation, Market Growth and Compe

Added: (Fri Apr 13 2018)

Pressbox (Press Release) - Global Infertility Testing Market by Regional Outlook, End User, Top Key Players, Competitors, Share Analysis and Forecast to 2024
Global Infertility Testing Market is expected to reach 22,421.79 million by 2024 from 13,347.10 million in 2016, at a CAGR of 6.8% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.Request a Sample Copy: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-infertility-testing-market
Global Infertility Testing Market by Type (Female Infertility Testing, Male Infertility Testing), By Test Kits (Human Follicular Stimulating Hormone (FSH) Urine Test Kits, Luteinizing Hormone (LH) Urine Test Kits, Human Chorionic Gonadotropin (HCG) Hormone Blood Test Kits, Others), By Prescription Mode (Prescription-Based, Over The Counter (OTC) Based), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, Pharmacies & Drug Stores), By End User (Fertility Centers, Hospitals And Clinics, Research Institutes, Cryobanks), By Geography (North America, Europe, Asia-Pacific, South America, Middle East And Africa) Industry Trends and Forecast to 2024

Market Segmentation:
The global infertility testing market is segmented on the basis of type, test kits, prescription mode, distribution channel and end user.
On the basis of test kits are further sub divided into human Follicular Stimulating Hormone (FSH) urine test kits, luteinizing hormone (LH) urine test kits, human chorionic gonadotropin (HCG) hormone blood test kits and others.
On the basis of prescription mode, the global infertility testing market is segmented into prescription-based and over the counter (OTC) based.
On the basis of end user, the global infertility testing market is classified into fertility centers, hospitals and clinics, research institutes and cryobanks.
.
…Continued
For More Information: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-infertility-testing-market
Key Drivers:
The major factors driving the growth of this market are significant decline in fertility rates, increasing number of fertility clinics, rising public awareness among the female population, increasing number of gynaecological disorders and technological advancements and innovative testing products. On the other hand, high cost of ovulation testing and accuracy issues with testing kits may hinder the growth of the market.
Key Points:
The Merck KGaA is going to dominate the global infertility market followed by Procter & Gamble, bioMérieux SA and other players operating in this market are include Babystart Ltd, Biozhena Corporation, Quidel Corporation, Alere Inc., SPD Swiss Precision Diagnostics GmBH, Proctor & Gamble, SCSA Diagnostics, Inc., among others.
TABLE OF CONTENTS GLOBAL INFERTILITY TESTING MARKET
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL INFERTILITY TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. SIGNIFICANT DECLINE IN FERTILITY RATES
3.1.2. RISING PUBLIC AWARENESS AMONG THE FEMALE POPULATION
3.1.3. INCREASING NUMBER OF GYNAECOLOGICAL DISORDERS
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIVE TESTING PRODUCTS
3.2. RESTRAINTS
3.2.1. HIGH COST OF OVULATION TESTING
3.2.2. ACCURACY ISSUES WITH TESTING KITS
3.3. OPPORTUNITIES
3.3.1. REDUCTION IN THE COST OF INFERTILITY TREATMENT
3.3.2. EMERGENCE OF COMBINATION TESTING KITS
3.4. CHALLENGES
3.4.1. STRINGENT REGULATORY SCENARIO
3.4.2. INFERTILITY CONSIDERED AS SOCIAL TABOO
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL INFERTILITY TESTING MARKET, BY TYPE
6.1. OVERVIEW
6.2. FEMALE INFERTILITY TESTING
6.2.1. OVULATION TESTING
6.2.2. HYSTEROSALPINGOGRAPHY
6.2.3. LAPAROSCOPY
6.2.4. TRANSVAGINAL ULTRASOUND
6.2.5. OVARIAN RESERVE TESTING
6.2.6. HORMONE TESTING
6.2.7. OTHERS
6.3. MALE INFERTILITY TESTING
6.3.1. DNA FRAGMENTATION
6.3.2. OXIDATIVE STRESS ANALYSIS
6.3.3. SPERM PENETRATION ASSAY
6.3.4. COMPUTER AIDED SEMEN ANALYSIS
6.3.5. SPERM AGGLUTINATION ASSAY
6.3.6. MICROSCOPIC EXAMINATION
6.3.7. OTHERS
7. GLOBAL INFERTILITY TESTING MARKET, BY TEST KITS
7.1. OVERVIEW
7.2. FOLLICULAR STIMULATING HORMONE (FSH) URINE TEST KITS
7.3. LUTEINIZING HORMONE (LH) URINE TEST KITS
7.4. HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE BLOOD TEST KITS 67
7.5. OTHER TEST KITS
8. GLOBAL INFERTILITY TESTING MARKET, BY PRESCRIPTION MODE
8.1. OVERVIEW
8.2. PRESCRIPTION BASED
8.3. OVER THE COUNTER (OTC) BASED
9. GLOBAL INFERTILITY TESTING MARKET, BY DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. HOSPITALS PHARMACIES
9.3. ONLINE PHARMACIES
9.4. PHARMACIES & DRUG STORES
10. GLOBAL INFERTILITY TESTING MARKET, BY END USERS
10.1. OVERVIEW
10.2. FERTILITY CENTERS
10.3. HOSPITALS AND CLINICS
10.4. RESEARCH INSTITUTES
10.5. CRYOBANKS
11. GLOBAL INFERTILITY TESTING MARKET, BY GEOGRAPHY
11.1. OVERVIEW
11.2. NORTH AMERICA
11.2.1. U.S.
11.2.2. CANADA
11.2.3. MEXICO
11.3. EUROPE
11.3.1. GERMANY
11.3.2. FRANCE
11.3.3. U.K.
11.3.4. ITALY
11.3.5. SPAIN
11.3.6. RUSSIA
11.3.7. TURKEY
11.3.8. BELGIUM
11.3.9. NETHERLANDS
11.3.10. SWITZERLAND
11.3.11. REST OF EUROPE
11.4. ASIA-PACIFIC
11.4.1. JAPAN
11.4.2. CHINA
11.4.3. INDIA
11.4.4. SOUTH KOREA
11.4.5. AUSTRALIA
11.4.6. SINGAPORE
11.4.7. THAILAND
11.4.8. MALAYSIA
11.4.9. INDONESIA
11.4.10. PHILIPPINES
11.4.11. REST OF ASIA PACIFIC
11.5. SOUTH AMERICA
11.5.1. BRAZIL
11.5.2. REST OF SOUTH AMERICA
11.6. MIDDLE EAST AND AFRICA
11.6.1. SOUTH AFRICA
11.6.2. REST OF MIDDLE EAST & AFRICA
12. GLOBAL INFERTILITY TESTING MARKET, COMPANY LANDSCAPE
12.1. COMPANY SHARE ANALYSIS: GLOBAL
12.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3. COMPANY SHARE ANALYSIS: EUROPE
12.4. COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13. COMPANY PROFILES
13.1. BABYSTART LTD
13.1.1. COMPANY OVERVIEW
13.1.2. BABYSTART LTD: COMPANY SNAPSHOT
13.1.3. PRODUCT PORTFOLIO
13.1.4. RECENT DEVELOPMENTS
13.2. BIOZHENA CORPORATION
13.2.1. COMPANY OVERVIEW
13.2.2. BIOZHENA CORPORATION:COMPANY SNAPSHOT
13.2.3. PRODUCT PORTFOLIO
13.2.4. RECENT DEVELOPMENTS
13.3. QUIDEL CORPORATION
13.3.1. COMPANY OVERVIEW
13.3.2. QUIDEL CORPORATION: REVENUE ANALYSIS
13.3.3. PRODUCT PORTFOLIO
13.3.4. RECENT DEVELOPMENTS
13.4. ALERE INC.
13.4.1. COMPANY OVERVIEW
13.4.2. ALERE INC.: REVENUE ANALYSIS
13.4.3. PRODUCT PORTFOLIO
13.4.4. RECENT DEVELOPMENTS
13.5. BIOMÉRIEUX
13.5.1. COMPANY OVERVIEW
13.5.2. BIOMÉRIEUX: REVENUE ANALYSIS
13.5.3. PRODUCT PORTFOLIO
13.5.4. RECENT DEVELOPMENTS
13.6. SPD SWISS PRECISION DIAGNOSTICS GMBH
13.6.1. COMPANY OVERVIEW
13.6.2. SPD SWISS PRECISION DIAGNOSTICS GMBH: COMPANY SNAPSHOT
13.6.3. PRODUCT PORTFOLIO
13.6.4. RECENT DEVELOPMENTS
13.7. PROCTER & GAMBLE
13.7.1. COMPANY OVERVIEW
13.7.2. PROCTER & GAMBLE: REVENUE ANALYSIS
13.7.3. PRODUCT PORTFOLIO
13.7.4. RECENT DEVELOPMENTS
13.8. SCSA DIAGNOSTICS, INC.
13.8.1. COMPANY OVERVIEW
13.8.2. SCSA DIAGNOSTICS, INC: COMPANY SNAPSHOT
13.8.3. PRODUCT PORTFOLIO
13.8.4. RECENT DEVELOPMENTS
13.9. ANDROLOGY SOLUTIONS
13.9.1. COMPANY OVERVIEW
13.9.2. ANDROLOGY SOLUTIONS: COMPANY SNAPSHOT
13.9.3. PRODUCT PORTFOLIO
13.9.4. RECENT DEVELOPMENTS
13.10. ATLAS MEDICAL UK
13.10.1. COMPANY OVERVIEW
13.10.2. ATLAS MEDICAL UK: COMPANY SNAPSHOT
13.10.3. PRODUCT PORTFOLIO
13.10.4. RECENT DEVELOPMENTS
13.11. HALOTECH DNA
13.11.1. COMPANY OVERVIEW
13.11.2. HALOTECH DNA: COMPANY SNAPSHOT
13.11.3. PRODUCT PORTFOLIO
13.11.4. RECENT DEVELOPMENTS
13.12. SA SCIENTIFIC
13.12.1. COMPANY OVERVIEW
13.12.2. SA SCIENTIFIC: COMPANY SNAPSHOT
13.12.3. PRODUCT PORTFOLIO
13.12.4. RECENT DEVELOPMENTS
13.13. GEM MEDIC TECHNOLOGY CO.,LTD
13.13.1. COMPANY OVERVIEW
13.13.2. GEM MEDIC TECHNOLOGY CO., LTD: COMPANY SNAPSHOT
13.13.3. PRODUCT PORTFOLIO
13.13.4. RECENT DEVELOPMENTS
13.14. MERCK KGAA
13.14.1. COMPANY OVERVIEW
13.14.2. MERCK KGAA: REVENUE ANALYSIS
13.14.3. PRODUCT PORTFOLIO
13.14.4. RECENT DEVELOPMENTS
14. RELATED REPORTS

Access Full Report: http://databridgemarketresearch.com/reports/global-infertility-testing-market/
About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

Submitted by:Data Bridge Market Research
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.